First Patients in NIH ACTIV-3 Clinical Trial Enroll in Dallas

On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

Read more

Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19

As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.

Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.

Read more

Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19

Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Read more

Research and innovation as an essential function amid the COVID-19 pandemic

Necessity being the mother of invention, Houston Methodist clinicians, researchers and staff have collaborated on a number of clinical device and research innovations in response to COVID-19. Houston Methodist Academic Institute leadership has continually emphasized translational research in new technologies.

Read more

Baylor Scott & White Research Institute Exploring Potential Prevention Options, Therapies for COVID-19

Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health, is bringing clinical trials online at an unprecedented pace in response to COVID-19. A COVID-19 therapeutic task force of more than 20 multidisciplinary researchers positioned across the state of Texas has been putting their expertise in infectious disease, cardiology, immunology, molecular biology, and other specialties together to explore research opportunities for experimental prevention and treatment options and to develop investigator-initiated studies.

Read more